Adaptive Biotechnologies Corp
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
ADPT$30.26+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Noncontrolling · TotalShareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | (Loss) Gain | Deficit | Interest | Equity | |
| Balance at December 31, 2022 | 143,105,002 | $14 | $1,387,349 | $(4,116) | $(919,082) | $(67) | $464,098 |
| Issuance of common stock for cash upon exercise of stock options | 470,405 | — | 2,245 | — | — | — | 2,245 |
| Vesting of restricted stock units | 1,506,864 | — | — | — | — | — | — |
| Share-based compensation | — | — | 62,908 | — | — | — | 62,908 |
| Other comprehensive income | — | — | — | 4,331 | — | — | 4,331 |
| Net loss | — | — | — | — | (225,250) | (54) | (225,304) |
| Balance at December 31, 2023 | 145,082,271 | 14 | 1,452,502 | 215 | (1,144,332) | (121) | 308,278 |
| Issuance of common stock for cash upon exercise of stock options | 103,800 | — | 241 | — | — | — | 241 |
| Vesting of restricted stock units, net | 2,587,673 | — | — | — | — | — | — |
| Share-based compensation | — | — | 53,610 | — | — | — | 53,610 |
| Other comprehensive loss | — | — | — | (49) | — | — | (49) |
| Net loss | — | — | — | — | (159,492) | (103) | (159,595) |
| Balance at December 31, 2024 | 147,773,744 | 14 | 1,506,353 | 166 | (1,303,824) | (224) | 202,485 |
| Issuance of common stock for cash upon exercise of stock options | 2,398,663 | 1 | 17,878 | — | — | — | 17,879 |
| Vesting of restricted stock units and market-based restricted stock units | 3,607,011 | — | — | — | — | — | — |
| Share-based compensation | — | — | 51,483 | — | — | — | 51,483 |
| Capital contributions for Digital Biotechnologies, Inc. | — | — | 6,134 | — | — | 6,390 | 12,524 |
| Other comprehensive income | — | — | — | 87 | — | — | 87 |
| Net (loss) income | — | — | — | — | (59,499) | 42 | (59,457) |
| Balance at December 31, 2025 | 153,779,418 | $15 | $1,581,848 | $253 | $(1,363,323) | $6,208 | $225,001 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.